Cargando…

A Beam Projection-Based Modified Gamma Analysis Scheme for Clinically Interpretable Pre-Treatment Dose Verification

PURPOSE: To investigate a novel gamma analysis system for dose verification results in terms of clinical significance. METHODS AND MATERIALS: The modified scheme redefined the computational domain of the conventional gamma analysis with the projections of beams and the regions of interest (ROI). We...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yiling, Yin, Gang, Wang, Jie, Zhao, Yue, Liu, Min, Lang, Jinyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040583/
https://www.ncbi.nlm.nih.gov/pubmed/33889062
http://dx.doi.org/10.1177/15593258211001676
Descripción
Sumario:PURPOSE: To investigate a novel gamma analysis system for dose verification results in terms of clinical significance. METHODS AND MATERIALS: The modified scheme redefined the computational domain of the conventional gamma analysis with the projections of beams and the regions of interest (ROI). We retrospectively studied 6 patients with the conventional and the modified gamma analysis schemes while compared their performances. The cold spots ratio of the planning target volume (PTV) and the hot spots ratio of the organs at risk (OAR) were also computed by the modified scheme to assess the clinical significance. RESULTS: The result of the gamma passing rate in the modified method was conformable to that in the conventional method with a cut-off threshold of 5%. The cold spots ratio of PTV and hot spots ratio of OAR were able to be evaluated by the modified scheme. For an introduced 7.1% dose error, the discrimination ratio in gamma passing rate of the conventional method was lower than 2%, while it was improved to 5% by the modified method. CONCLUSIONS: The modified gamma analysis scheme had a comparable quality as the conventional scheme in terms of dose inspection. Besides, it could improve the clinical significance of the QA result and provide the assessment for ROI-specific discrepancy. The modified scheme could also be conveniently integrated into the conventional dose verification process, benefiting the less developed regions where high-end 3D dose verification devices are not affordable.